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Purpose. A new inhaler (Medspray
®) for pulmonary drug delivery based on the principle of Rayleigh
break-up has been tested with three different spray nozzles (1.5; 2.0 and 2.5 μm) using aqueous 0.1%
(w/w) salbutamol and 0.9% (w/w) sodium chloride solutions.
Materials and methods. Particle size distributions in the aerosol were measured with the principles of
time of flight (APS) and laser diffraction (LDA).
Results. The Medspray
® inhaler exhibits a highly constant droplet size distribution in the aerosol during
dose emission. Droplets on the basis of Rayleigh break-up theory are monodisperse, but due to some
coalescence the aerosols from the Medspray
® inhaler are slightly polydisperse. Mass median
aerodynamic diameters at 60 l.min
−1 from APS are 1.42; 1.32 and 1.27 times the theoretical droplet
diameters (TD’s) and median laser diffraction diameters are 1.29; 1.14 and 1.05 times TD for 1.5; 2.0 and
2.5 μm nozzles (TD: 2.84; 3.78 and 4.73 μm respectively).
Conclusions. The narrow particle size distribution in the aerosol from the Medspray
® is highly
reproducible for the range of flow rates from 30 to 60 l.min
−1. The mass median aerodynamic droplet
diameter can be well controlled within the size range from 4 to 6 μm at 60 l.min
−1.
KEY WORDS: aerodynamic particle sizer; laser diffraction technique; monodisperse aerosol; pulmonary
drug delivery; Rayleigh break-up; wet nebulisation.
INTRODUCTION
In the past decades it has become clear that drug
deposition targeting to a specific site in the respiratory tract
requires sophisticated technology. Irrespective of whether the
drug is in the dry or in the wet state, its aerodynamic size
distribution, the inspiratory manoeuvre with which the drug is
inhaled and the moment of aerosol release in the inhaled air
stream are of decisive importance (1). Many different
technologies have been presented to produce and deliver
dry or wet aerosols under the required conditions. They
include various new wet aerosol generation principles (2–4),
particle engineering technologies to improve aerosolisation of
drug particles in dry powder inhalers (5), techniques that
control the inhalation manoeuvre (6) or link the aerosol
release to this manoeuvre (7). Several reviews on new
principles for wet aerosols have appeared (1–4). They
produce so-called ‘soft mist’ aerosols either by mechanical,
thermo-mechanical or by electro-mechanical means. The
advantages mentioned for such devices are the use of
propellant-free (simple) drug solutions and the production
of slowly moving aerosols. It has been reported that some of
these new nebulisers produce well controlled and rather
narrow droplet size distributions (2). However, this depends
on the aerosol generation principle used and may be
influenced by the inspiratory flow rate and the formulation
being nebulised. For example, for the AERx, it has been
shown that more than 90% of the particles may be within the
narrow size range from 1 to 3 μ (8).
Particles in a narrow size range potentially improve drug
targeting in the lungs, providing that the inspiratory flow
manoeuvre can be well controlled. It has been shown that
peripheral deposition in patients with cystic fibrosis can be
maximised by controlling the flow rate between 0.25 and
0.5 l.s
−1, using monosized particles of 2–3 μ (6). In a different
study with 3 μ particles, it was found that total lung deposition
may vary between 20 and 95% when the breathing pattern is
not controlled (9). Not only differences in the flow
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laser diffraction analysis).manoeuvre, but also differences in administration devices
(10) and patient characteristics (11) may explain why
different particle sizes have been recommended for drugs
with the same target area, e.g. for salbutamol within the range
from 2.8 (12)t o6μ (13). A particle size in this range for a
bronchodilator, for which the target area is in not in the
alveolar region but rather in the central and upper airways,
has been shown effective in a study with monodisperse
aerosols (14). It could be demonstrated that smaller
particles (1.5–3 μm) achieve greater total lung deposition,
farther distal airway penetration and more peripheral
deposition, whereas larger particles (6 μm) result in greater
bronchodilatory effect for drugs like salbutamol. However, it
was also reported that increasing the flow rate decreases total
lung deposition for large particles due to increased
oropharyngeal deposition (14).
The aim of this study was to show that the principle of
Rayleigh break-up can be a low cost, yet highly effective and
robust alternative for near-monodisperse aerosol generation.
A simple hand-held, preservative-free, non-pressurised
metered dose inhaler (Medspray
®) has been developed on
the basis of this principle, containing micro engineered
nozzles produced with wafer stepper lithography and etching
techniques. Different nozzle diameters in different geometries
have been tested with two different particle sizing techniques:
a laser diffraction apparatus (LDA) and an aerodynamic
particle sizer (APS). Also the reproducibility of the delivered
dose from the Medspray
® was tested.
MEDSPRAY
® DESIGN AND PRINCIPLE
OF OPERATION
The Medspray
® inhaler concept consists of a spray
nozzle in combination with a specially designed pump system.
The liquid is dispersed into droplets by pressing the drug
solution through an array of nozzles with mechanical means,
and a special mouthpiece that mixes the generated droplets
with the air stream inhaled by the patient.
Theoretically, the break-up of a liquid jet from a circular
single orifice is in droplets of uniform size if the break-up is
within the Rayleigh regime (15). A major contribution to the
understanding of jet break-up mechanisms has been given by
Weber (16) who extended Rayleigh’s basic analysis to include
the viscosity of the liquid. According to Weber, the droplet size
for pure water at room temperature is 1.95 times the diameter
of the nozzle. The arrangement (number and diameter) of
nozzle arrays used for this study is such that the total area for
passage of the drug solution is the same for all droplet sizes.
The Medspray
® hand-held inhaler is as simple as a
metered dose inhaler regarding drug formulation (non-
pMDI) and the handling by the patient is similar to that of
a pMDI (Fig. 1). This has the advantage that patients being
used to administer their medication with an mdi, can directly
switch over to the Medspray
® without requiring intensive
training. One major difference with MDI’s is the relatively
low velocity of the aerosol from the Medspray
® inhaler
however. The aerosol is discharged into a Venturi-like
mouthpiece channel inside which mixing of the droplets with
the inhaled air occurs. The special shape of the mouthpiece
and an air flow resistance on its inlet help to guide the patient
towards a flow rate in the range between 30 and 60 l.min
−1.
The air flow perpendicular to the initial droplet flow prevents
impaction of the droplets with the inner mouthpiece walls and
also minimizes droplet coalescence. The geometry of the
mouthpiece channel slows down the aerosol particles before
they leave the mouthpiece and enter the mouth. At 30 l.min
−1
the maximum aerosol velocity leaving the mouthpiece is
below 4 m.s
−1, which is considerably lower than the aerosol
velocity from classic (CFC) MDI’s( 17). Moreover, particle
thrust is entirely determined by the drag force of the
inspiratory flow and not by the aerosol generating principle,
preventing that the aerosol particles are substantially
deposited in the oropharynx.
The Medspray
® inhaler is suitable for nebulising any
solution with viscosity below 10 mPas, which includes most
protein and peptide solutions, and the drug solution is stored
in a container with a mechanical pump system. Different
nozzles can be used to target a special site in the lung. The
patient starts dose administration by inhaling via the mouth-
piece. The patient then actuates the inhaler by pressing the
dose release button on top of the inhaler which loads the
spring between this button and the drug container. The spring
load will start the release of the contents of the pump system
through the spray nozzle and this makes dose release through
the spray nozzle independent of the pressure or speed with
which the patient presses the dose release button of the
Medspray
®. Typically, the dose from the tested Medspray
® is
30 μl, which takes about 2 s to be aerosolised. Because of this
prolonged release of drug, the hand-lung coordination is not
particularly critical. Even if a patient presses the button
before the inhalation has been started, most of the generated
aerosol will still be delivered to the lungs. At a flow rate of
60 l.min
−1, the total dose will be delivered in 2 l of inhaled air
which is in agreement with draft guidelines on inhalanda.
MATERIALS AND METHODS
Medspray
® inhalers used for the experiments were
prototypes prepared for a clinical study. Spray nozzles with
three different nozzle diameters were tested with 0.1% (w/w
salbutamol) and/or 0.9% (w/w sodium chloride) aqueous
solutions. The nozzles were selected on the basis of the
outcome of preliminary experiments in which the effect of
nozzle array (distance between nozzles and nozzle line-ups)
Fig. 1. Drawing of the Medspray
® hand-held inhaler showing its
MDI-like appearance.
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® Wet Aerosol Inhaleron droplet coalescence was investigated as function of the air
velocity through the mouthpiece. The results presented in this
study are for spray nozzles of 1.5; 2.0 and 2.5 μm diameter.
Sodium chloride solutions (20 ml ampoules) were
purchased (Braun, Germany) and for the salbutamol solu-
tions Ventolin (ampoules with 2.5 mg in 2.5 ml) were pur-
chased (GSK, UK). Viscosities of the solutions were
measured with a rotation viscosimeter (Brookfield Engineer-
ing Laboratories, van Oortmerssen, The Netherlands) at a
rotation speed of 250 rpm. The solutions were used as such or
as a mixture with a ratio for salbutamol to sodium chloride of
1:2, yielding a salbutamol dose of 10 μgi n3 0μl nebulization
liquid. Drug containers with a special pump system were filled
in house with 7.5 ml of the prepared drug solutions, which is
the quantity necessary for the administration of 250 doses.
Consistency of metered dose from the pump system was
measured by weighing the pump before and after each
individual emitted dose on an analytical balance with an
error percentage of ± 0.033% over the whole range of 200
doses at various flow rates in the range from 20 to 90 l.min
−1.
Cumulative volume distributions as function of the
droplet diameter for the aerosols from the Medspray
® inhaler
were measured with a HELOS BF/MAGIC laser diffraction
apparatus (Sympatec, Germany) using a special inhaler
adapter INHALER 2000 (18). No counter flow nor sheath
flow was applied through the adapter. All single measure-
ments were triggered on an optical signal of 0.2% on channel
30 and conducted with a 100 mm (R3) lens for the particle
size range 0.9–175 μm. Calculations were based on the
Fraunhofer theory because the optical parameters for the
drug solutions as function of the droplet size distribution are
unknown. It has been shown that Fraunhofer diffraction is
quite accurate for predominantly unimodal products and
multimodal powders for which the modes are quite close
and clearly within the declared limits of the lens (19).
Different flow rates were adjusted to study the effect of air
velocity through the mouthpiece on droplet evaporation and
coalescence. Because the droplets are generated from aque-
ous solutions with low drug concentrations (density
approaches 1 g.cm
−3) and because droplets are spherical,
the laser diffraction diameters are supposed to match
perfectly well the aerodynamic droplet diameters. To follow
the droplet size distribution as function of the emission time,
time sliced measurements were also conducted with an
interval time of 100 ms. Measuring was started manually
before a dose was released into the laser beam. Data points
for presentation were selected on the basis of the optical
concentration to mark the start of dose emission (Copt >
0.25%) and upon time (approx. 2 s) for the end of dose
release from the inhaler’s mouthpiece.
For assessing the true aerodynamic diameters of 0.9%
sodium chloride droplets (aqueous solution), an aerodynamic
particle sizer TSI model 3310 (TSI Inc., USA) was used (with
Phantom particle and Stokes correction) in combination with
a TSI 100 to 1 aerosol dilutor model 3302A. For these
measurements, a special technique was applied. The aerosols
from the Medspray
® inhalers were sampled in a 10 l cylindrical
metal spacer tube with 0.1m inner diameter at flow rates of 30
and 60 l.min
−1. While the aerosol was collected, the droplets
dried by water evaporation and the dry particles were next
introduced to the measuring principle of the APS at a flow
rate of 5 l.min
−1. As the APS distinguishes individual particles
on the basis of time of flight, particle counts (in narrow size
classes) are obtained which yield number distributions with a
high resolution. This enables to distinguish particles obtained
from drying of single droplets, from those derived from
multiplets (being the result of droplet coalescence). From the
known density (2.2 g.cm
j3) and dynamic shape factor (1.08)
of the dried cubic sodium chloride particles (20)a sw e l la st h e
original salt concentration in the aerosolised solution (0.9% w/
w), the number distributions of dried particles can be re-
calculated in the number distributions of the original droplets
and ultimately in volume and mass distributions. The mass
median aerodynamic diameters thus obtained have been
compared with the volume median diameters from laser
diffraction measurement.
Scanning electron micrographs (SEM pictures) of dried
particles for APS-measurement were taken with a Jeol 5610
JP microscope. Particles were sampled by placing the drying
tube in vertical position over a collection plate. Aerosol
particles entering the tube from the inhaler with controlled air
flow dried while travelling through the tube and deposited on
the plate. Prior to investigation, the samples were coated with
5 nm of Au/Pd in a sputtering device.
RESULTS AND DISCUSSION
Traditionally, multi-stage cascade impactors and aerody-
namic particle sizers are used for medical aerosol character-
isation as they yield mass, respectively number distributions
as function of the aerodynamic diameter which governs
particle deposition in the respiratory tract. It has recently
been recognised however, that laser diffraction analysis may
produce very meaningful results too (21). This technique has
the special advantage of following size distributions in the
aerosol continuously with so-called time sliced measurements.
Also droplet evaporation and coalescence, both as function of
the inspiratory flow rate, can be monitored only with laser
diffraction technique. For these reasons, this study was
completed using both APS and LDA. Because it was found
that the viscosity of the 0.9% saline and 0.1% salbutamol
solutions are the same (and equal to that of pure water, being
1.00 mPa.s), the droplet size distributions from the Med-
spray
® nozzles are the same for all three liquids under the
same circumstances.
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Fig. 2. Consistency of metered dose from the pump system for 0.9%
sodium chloride solution.
1188 de Boer et al.Figure 2 shows an example of the consistency of the dose
metered by the pump system for a 0.9% sodium chloride
(saline) solution using a nozzle diameter of 2.5 μm. Metered
doses are expressed as percent of the targeted value. The
variation (maximum and minimum of individual doses) after
priming of the nozzle (10 doses) is within the ± 5% range and
there is no drop-off in metered dose near the end of lifetime
(200 doses). Only within the first ten doses there is a gradual
increase towards the targeted value, meaning that the inhaler
has to be primed. However, current design improvements are
focused on minimising this starting effect. Retention in the
mouthpiece of the Medspray
® inhaler for all nozzle types in
the range of flow rates between 30 and 60 l.min
−1 is between
5 and 10% of the metered dose from the nozzle, decreasing
the delivered dose from the inhaler to 90–95% of the metered
value.
A typical droplet volume distribution curve obtained
with the special APS technique (including droplet drying) of
an aerosol from a saline solution is shown in Fig. 3. For the
example, a 2.5 μm nozzle has been used and the aerosol was
drawn into the drying cylinder on the APS with a flow rate of
60 l.min
−1. SEM investigation confirmed that the dried
particles were perfectly cubic, proving that crystalline solid
particles were obtained with known density and dynamic
shape factor and that the presented re-calculation into
original droplet sizes is correct. On the basis of Rayleigh
break-up droplets of approx. 1.9 times the nozzle diameter
(2.5 μm) would be expected. Figure 3 shows that the first
peak indeed corresponds with a droplet diameter slightly less
than 5 μ. A secondary peak is visible at a position just over
6 μm and the peak is skewed on the side of larger particles
which is proof for the existence of doublet and triplet droplets
in the aerosol as the result of coalescence. By merging of two
droplets, the volume is doubled, but the diameter is increased
only by a factor 1.26 (d = 5.99 μm). Similarly the diameter of
a triplet is only 1.44 times the diameter of a singlet (d =
6.84 μm). This results in different ratios of mass median
aerodynamic diameter (MMAD) from APS-measurement to
calculated droplet diameter on the basis of Weber’s break-up
theory for different nozzles, as shown in Table I. In spite of the
occurrence of some coalescence, the droplet size distributions
from APS are relatively narrow as presented in Fig. 4, whereas
the volume median aerodynamic diameters vary only from
1.23 to 1.38 times the expected theoretical diameters. Because
the size distributions are not log-normal, the calculation of
geometric standard deviations is arguable. As an alternative,
the relative spans of the size distributions have been calculated
{(D90 − D10)/D50}, which are presented in Table I too.
With laser diffraction technique droplets can be mea-
sured before they evaporate. For droplets from aqueous drug
solutions which almost have unit density and are perfectly
spherical, laser diffraction diameters differ not noticeable
from aerodynamic diameters. However, size distributions calcu-
lated with the Fraunhofer approximation may show inaccura-
cies for particles in the size range below 1–2 μm, depending on
the size distribution in the aerosol (22). Although the Lorenz–
Mie model is more complete in terms of describing all possible
interactions of the laser beam with the particles, and therefore
theoretically more correct, this model can not be applied for
drug solutions for which the optical parameters as function of
the size distribution are not known.
For the laser diffraction measurements the same inhalers
and the same 0.9% w/w sodium chloride solution were used
as for the measurements with the APS. A typical volume
frequency distribution curve (as function of the diameter)
from laser diffraction analysis for the aerosol from the 2.5 μm
nozzle spraying an aqueous 0.9% sodium chloride solution at
60 l.min
j1 is shown in Fig. 5. The results are not directly
comparable with those presented in Fig. 3 from APS showing
a number distribution in which particles consisting of an
integer number of primary entities produce discrete peaks.
The volume frequency distribution curve in Fig. 5 does not
show secondary or ternary peaks on the side of the larger
particles but some fines in the size range between 1 and 2
micron which are the result of Fraunhofer overestimation of
fines. These small particles do not exist as can be concluded
from the APS measurement (Fig. 3). For the specific example
in Fig. 5, a correction can be made (closed symbols), because
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Fig. 3. Number frequency distribution as function of aerodynamic
droplet diameter for the aerosol from a 2.5 μm spray nozzle for an
aqueous 0.9% sodium chloride solution delivered at an air flow rate
of 60 l.min
−1 from the Medspray
® inhaler into the drying tube of the
aerodynamic particle sizer.
Table I. Comparison of Theoretical Droplet Diameters, Mass Median Aerodynamic Diameters and the Relative Spans (D90−D10/D50) of the
Mass Distributions from Aerodynamic Particle Sizing
Nozzle
Theoretical Droplet
Diameter
a (TD)
Mass Median Aerodynamic
Diameter (MMAD)
Ratio of MMAD
to TD
Relative Span of the Size
Distribution (D90D10)/D50
(mm) (mm) (mm) (j)( j)
1.5 2.93 4.03 1.38 0.60
2.0 3.90 4.98 1.28 0.70
2.5 4.88 5.99 1.23 0.58
Aerosol delivery at an air flow rate of 60 l.min
−1
aCalculated using Weber’s equation for the optical wavelength for droplet formation and the physical constants for pure water
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® Wet Aerosol Inhalerthe peaks for the imaginary fines and the aerosol particles are
completely separated from each other. For the corrected
curve, 90% of the total volume is in particles in the size range
between 3 and 9 μm and the volume median diameter
(VMD) is 5.50 μm. This is quite close to the calculated
droplet diameter of single entities (4.88 μm) and only 10%
higher than the VMD for the uncorrected curve (4.99 μm for
the open symbols). For comparison, the MMAD for the
2.5 μm nozzle from APS measurement is 5.99 μm. For the 1.5
and 2.0 μm nozzles a correction of the laser diffraction data
for the imaginary fines is not possible because the peaks for
the fines and the aerosol particles partly overlap each other.
However, thanks to the much smaller volume median
diameters for the aerosols from these nozzles, the occurrence
of ‘Fraunhofer fines’ is less pronounced (Fig. 6).
In spite of the calculation of some imaginary fines with
the Fraunhofer approximation, the relative spans obtained
from laser diffraction technique are even slightly smaller than
those obtained from aerodynamic particle sizing (Table II
versus Table I). Whereas the data from LDA are of some-
what lower confidence in the size classes for the smallest
particles, the APS data presented may show some inaccuracy
for the coarsest particles. This could be the result of the
applied technique for particle collection and drying in a
spacer tube, which may have increased the number of
particles being coalesced.
The effect of droplet evaporation on the laser diffraction
results has been investigated by elongating the distance
between the inhaler’s mouthpiece and the laser beam with a
tube of 500 mm. This decreased the median droplet diameter
foranaerosolfrom0.9%sodiumchloridesolutionat60l.min
j1
(2.5 μm nozzle) only by 6.2%, whereas the relative span of
the size distribution hardly changed (from 1.39 to 1.35). This
suggests that no classification (e.g. by sedimentation in the
inlet tube) or droplet coalescence occurred during laser
diffraction measurement. Also the effects of viscosity and
temperature on the droplet size distribution in the aerosol
were investigated. It was found that the temperature within
the range of values to be expected during normal use has no
effect, whereas the viscosity increases the droplet size (< 5%
for the drug solutions tested) as predicted by Weber (16).
There is an effect of flow rate on droplet coalescence however.
This is shown in Fig. 7, comparing the volume median diam-
eters of all three nozzles with each other at 30 and 60 l.min
j1
through the Medspray
® inhaler. On average for all three
nozzles, increasing the flow rate from 30 to 60 l.min
j1
decreases the volume median droplet diameter by 11.4%,
corresponding with a reduction of droplet mass by 38%. This is
the result of a considerable reduction in the number of
multiplets, which may partly compensate for the increased
losses in the oropharynx when the flow rate is increased from
30 to 60 l.min
j1. That the decrease in volume median diameter
is not the result of droplet evaporation seems to be confirmed
by the observation that particularly the X90-value is reduced.
The results from time sliced (laser diffraction) measure-
ment show that the droplet size distribution is extremely
constant during dose emission. For the example of the 2.5 μm
nozzle spraying a 30 μl salbutamol solution at a nebulization
rate of 15 μl.s
j1 (air flow rate through the Medspray
® inhaler
is 30 l.min
j1), this is shown in Fig. 8. The figure also shows
the high reproducibility in droplet size distribution between
two duplicate experiments.
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Fig. 4. Cumulative mass distribution curves as function of the aerody-
namic droplet diameter for the aerosols from an aqueous 0.9% sodium
chloride solution delivered at an air flow rate of 60 l.min
−1 from the
Medspray
® inhaler into the drying tube of the aerodynamic particle
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Fig. 5. Volume frequency distribution curves as function of the
droplet diameter for the aerosol from a 2.5 μm spray nozzle for an
aqueous 0.9% sodium chloride solution delivered at an air flow rate
of 60 l.min
−1 into the adapter of the laser diffraction apparatus from
the Medspray
® inhaler. Open symbols before, and closed symbols
after correction for the Fraunhofer overestimation of fines.
0
20
40
60
80
100
0.1 1 10 100
upper class limit (µm)
c
u
m
u
l
a
t
i
v
e
 
v
o
l
u
m
e
 
p
e
r
c
e
n
t
 
(
%
)
1.5 µm nozzle
2.0 µm nozzle
2.5 µm nozzle
Fig. 6. Cumulative volume distribution curves as function of the
droplet diameter for the aerosols from an aqueous 0.9% sodium
chloride solution delivered at an air flow rate of 60 l.min−1 into the
adapter of the laser diffraction apparatus from the Medspray
® inhaler
using 1.5; 2.0 and 2.5 μm spray nozzles. No corrections made for the
Fraunhofer overestimation of fines.
1190 de Boer et al.CONCLUSIONS
The results from this study show that the principle of
Rayleigh break-up can be used to aerosolise drug solutions
for inhalation very effectively. A simple, low cost, hand-held
inhaler (Medspray
®) has been made on the basis of this
principle, which has the simplicity (in handling) of a metered
dose inhaler. The inhaler exhibits excellent consistency of
delivered dose and the spring loaded dose release guarantees
that delivery rate (for the current design: 30 μl in 2 s) and
particle size distribution in the aerosol are very constant. The
two different techniques used to characterize the aerosol from
the Medspray
® inhaler, both produced polydisperse particle
size distributions in a narrow size range, although particles on
the basis of the Weber break-up theory are expected to be of
uniform size. To find out whether this is the result of errors
introduced by the measuring techniques used for the study, or
primarily that of droplet coalescence, the effect of flow rate
on droplet coalescence was investigated. It was found that
increasing the flow rate through the mouthpiece decreases
the degree of coalescence as it changes the distance between
the droplets in the flow direction. The degree of coalescence
is also influenced by the nozzle array and the droplet inertia.
This is the reason why the ratio of MMAD (or VMD) to
theoretical diameter was found to increase with decreasing
droplet diameter. Also a correction for the imaginary fines
obtained with Fraunhofer approximation for LDA as sizing
technique was made. For the 2.5 μm nozzle, it was found that
the correction does not change the polydisperse distribution
into monodisperse particles, although from this correction the
relative span of the aerosol from the 2.5 μm nozzle is reduced
from 1.4 to 0.8. In terms of geometric standard deviation
(GSD), which has not been presented for reasons explained
before (and is given only as indicative now), the cor-
responding value would be less than 1.4 (for spherical
particles GSD has unity). The results show that within the
range of flow rates from 30 to 60 l.min
−1 the droplet diameter
from the Medspray
® can be well controlled and is in fair
agreement with the theoretical droplet diameter, in spite of
the coalescence. This makes the Medspray
® a robust and
highly reproducible hand-held inhaler of which the aerosol
properties can easily be changed to meet the requirements for
targeting of a specific site of deposition in the human
respiratory lungs, simply by exchanging the spray nozzle.
Table II. Comparison of Theoretical Droplet Diameters, Volume Median Diameters and the Relative Spans (X90−X10/X50) of the Cumulative
Volume Distributions from Laser Diffraction Measurement
Nozzle
Theoretical Droplet
Diameter (TD)
Volume Median
Diameter (VMD)
Ratio of VMD
to TD
Relative Span of the
Size Distribution (X90jX10/X50)
(mm) (mm) (mm) (j)( j)
1.5 2.93 3.65 1.25 1.27
2.0 3.90 4.32 1.11 1.25
2.5 4.88 4.99 1.02 1.39
2.5 corrected 4.88 5.50 1.13 0.80
The corrected value for the 2.5 μm nozzle is after elimination of the Fraunhofer overestimation of fines.
Aerosol delivery at an air flow rate of 60 l.min
−1
Fig. 7. Effect of the air flow rate on the volume median droplet
diameter for aerosols from the Medspray
® inhaler using 1.5; 2.0 and
2.5 μm nozzles for spraying a 0.9% aqueous sodium chloride solution.
Data are the mean of two measurements with laser diffraction
technique. No corrections made for the Fraunhofer overestimation
of fines.
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Fig. 8. Time sliced measurements yielding the median droplet size
(circles) and optical concentration in the aerosol (diamonds)a s
function of the emission time (2 s) for the Medspray
® inhaler with a
2.5 μm nozzle spraying a salbutamol: saline solution in a ratio 1: 2.
Most error bars for the volume median diameter, indicating the
spread between two duplicate experiments at 30 l.min
−1, are within
the size of the symbols.
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